Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (Weighted Average) (2021 - 2025)

Indivior Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $125.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $125.0 million for Q4 2025, down 5.3% from a year ago — trailing twelve months through Dec 2025 was $125.0 million (down 5.3% YoY), and the annual figure for FY2025 was $125.0 million, down 5.3%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $125.0 million at Indivior Pharmaceuticals, roughly flat from $125.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for INDV hit a ceiling of $702.4 million in Q4 2021 and a floor of $124.0 million in Q1 2025.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $134.0 million (2024), compared with a mean of $183.1 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 80.21% in 2022 and later dropped 1.44% in 2023.
  • Indivior Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $702.4 million in 2021, then plummeted by 80.21% to $139.0 million in 2022, then dropped by 1.44% to $137.0 million in 2023, then decreased by 3.65% to $132.0 million in 2024, then dropped by 5.3% to $125.0 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $125.0 million (Q4 2025), $125.0 million (Q3 2025), and $125.0 million (Q2 2025) per Business Quant data.